他汀类药物使用与非酒精性脂肪性肝病患者肝细胞癌风险降低相关
该研究利用Optum去标识化Clinformatics数据库,纳入272,431例非酒精性脂肪性肝病(NAFLD)成人,采用Cox比例风险回归及逆概率治疗加权(IPTW)分析,发现他汀起始治疗者发生肝细胞癌(HCC)的风险较未使用者降低53%(HR 0.47;95%CI 0.36-0.60),且亲脂性与亲水性他汀均与HCC风险降低相关,累积限定日剂量超过600者风险降低70%(HR 0.30;95%CI 0.20-0.43)。
要点
- 在NAFLD成人中,他汀起始治疗与HCC风险降低53%相关(HR 0.47;95%CI 0.36-0.60)。
- 亲脂性他汀(HR 0.49;95%CI 0.37-0.65)与亲水性他汀(HR 0.40;95%CI 0.21-0.76)均与HCC风险降低相关。
- 他汀累积限定日剂量超过600者HCC风险降低70%(HR 0.30;95%CI 0.20-0.43),风险降低随剂量和疗程增加而增大。
核心结论
- 本研究提供了他汀起始治疗与NAFLD患者HCC风险降低相关的强证据,提示他汀可作为NAFLD患者的保护性药物以降低HCC风险。
研究设计与样本
- 基于Optum去标识化Clinformatics数据库的分析,纳入272,431例诊断为NAFLD的成人,采用Cox比例风险回归模型比较他汀起始者与未使用者发生HCC的风险,并采用逆概率治疗加权(IPTW)以减少潜在混杂。
主要发现
- 在272,431例NAFLD成人中,IPTW模型显示他汀起始者发生HCC的风险较未使用者降低53%(HR 0.47;95%CI 0.36-0.60)。
- 在具备纤维化-4指数数据的亚队列中,调整纤维化-4指数评分后,他汀起始与HCC风险降低56%相关(HR 0.44;95%CI 0.30-0.65)。
- 亲脂性他汀起始者HCC风险降低(HR 0.49;95%CI 0.37-0.65),亲水性他汀起始者HCC风险亦降低(HR 0.40;95%CI 0.21-0.76)。
- 他汀累积限定日剂量超过600的NAFLD患者发生HCC的风险降低70%(HR 0.30;95%CI 0.20-0.43),且风险降低幅度随他汀剂量和疗程增加而增大。
关键数值与推荐
- 他汀起始者 vs 未使用者:HCC风险HR 0.47(95%CI 0.36-0.60),即风险降低53%。
- 调整纤维化-4指数评分后:他汀起始者 vs 未使用者HCC风险HR 0.44(95%CI 0.30-0.65),即风险降低56%。
- 亲脂性他汀起始者HCC风险HR 0.49(95%CI 0.37-0.65);亲水性他汀起始者HCC风险HR 0.40(95%CI 0.21-0.76)。
- 他汀累积限定日剂量超过600者 vs 未使用者:HCC风险HR 0.30(95%CI 0.20-0.43),即风险降低70%。
临床怎么用
- 作者认为,他汀可作为NAFLD患者的保护性药物以降低HCC风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Recent evidence suggests potential clinical benefits of statin in cancer chemoprevention and treatment. Nonalcoholic fatty liver disease (NAFLD) is expected to become the leading cause of hepatocellular carcinoma (HCC). We aimed to investigate the association between statin initiation and the risk of HCC among patients with NAFLD. METHODS: In this study using the Optum de-identified Clinformatics database, Cox proportional hazards regression model was performed to determine the risk of HCC in statin initiators versus nonusers. We incorporated inverse probability of treatment weighting (IPTW) to minimize potential confounding. RESULTS: Among 272,431 adults with NAFLD diagnosis, IPTW model shows that statin initiators had 53% less risk of developing HCC compared with nonusers (hazard ratio [HR], 0.47; 95% confidence interval, 0.36-0.60). In the subcohort with fibrosis-4 index data available, statin initiation was associated with 56% hazard reduction of developing HCC in NAFLD after adjusting for fibrosis-4 index score (HR, 0.44; 0.30-0.65). The association between statin initiation and lower risk of HCC development was observed for both lipophilic statin (HR, 0.49; 0.37-0.65) and hydrophilic statin (HR, 0.40; 0.21-0.76). Moreover, we observed greater hazards reduction as the dose and duration of statin use increased. NAFLD patients with more than 600 cumulative defined daily doses of statin had 70% reduction in hazards of developing HCC (HR, 0.30; 0.20-0.43). CONCLUSIONS: Our study provides strong evidence for the association between statin initiation and reduced risk of HCC development in NAFLD patients. These findings imply that statin can be used as a protective medication for NAFLD patients to reduce the risk of HCC.
引用
- Zou B, Odden MC, Nguyen MH, et al. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2022. PMID: 35158055. doi:10.1016/j.cgh.2022.01.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。